Choosing Between TNF, IL 17, and JAK Inhibitors in Axial Spondyloarthritis – Dr. Jill Weintraub

Selecting the right therapy in axial spondyloarthritis requires more than symptom control—it requires structured monitoring and individualized risk assessment. In this segment, Dr. Jill Weintraub explains how standardized tools like the ASDAS score and BASDAI score support disease activity measures in axial spondyloarthritis, helping clinicians move toward a true treat-to-target in axial spondyloarthritis approach. From a rheumatology standpoint, she highlights how objective scoring improves decision-making in patients with arthritis, including ankylosing spondylitis and broader axial spondyloarthritis. Dr. Weintraub walks through how therapy choices are made among tnf inhibitors in axial spondylitis, il-17 inhibitors in spondyloarthritis, and jak inhibitors in axial spondyloarthritis. While tnf inhibitors have decades of safety data and proven benefit in preventing radiographic progression, infectious risk must be carefully weighed. Il-17 inhibitors in spondyloarthritis offer an alternative in certain patients, while jak inhibitors and other targeted synthetic DMARDs may be considered in specific scenarios after biologic therapy failure. What You’ll Learn In This Segment: ▶ How the ASDAS score and BASDAI score guide treatment adjustments ▶ Why structured disease activity measures in axial spondyloarthritis improve care ▶ The benefits and risks of tnf inhibitors in axial spondylitis ▶ When to consider il-17 inhibitors in spondyloarthritis ▶ The role of jak inhibitors in axial spondyloarthritis and safety considerations ▶ How biologic therapy selection in rheumatology differs from approaches in rheumatoid arthritis As Dr. Weintraub emphasizes, modern management of axial spondyloarthritis is highly personalized. Effective biologic therapy selection in rheumatology requires balancing disease severity, comorbidities, infection risk, and long-term safety—while using structured scores to ensure measurable progress. #axialspondyloarthritis #ankylosingspondylitis #rheumatology #biologictherapy #tnfinhibitors #jakinhibitors #mdnewsline